Safety and tolerability of NXY-059 for acute intracerebral hemorrhage : The CHANT trial

NXY-059 is a free radical-trapping neuroprotectant developed for use in acute ischemic stroke. To facilitate prompt administration of treatment, potentially before neuroimaging, we investigated the safety of NXY-059 in patients with intracerebral hemorrhage (ICH). We randomized 607 patients within 6...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stroke (1970) 2007-08, Vol.38 (8), p.2262-2269
Hauptverfasser:	LYDEN, Patrick D, SHUAIB, Ashfaq, RODICHOK, Larry, WASIEWSKI, Warren W, AHLBERG, Gabrielle, LEES, Kennedy R, DAVALOS, Antoni, DAVIS, Stephen M, DIENER, Hans-Christoph, GROTTA, James C, ASHWOOD, Tim J, HARDEMARK, Hans-Goren, SVENSSON, Hannah H
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease - therapy Adult Aged Aged, 80 and over Antioxidants - administration & dosage Antioxidants - adverse effects Benzenesulfonates - administration & dosage Benzenesulfonates - adverse effects Biological and medical sciences Brain - blood supply Brain - drug effects Brain - pathology Cardiovascular system Cerebral Arteries - pathology Cerebral Arteries - physiopathology Cerebral Hemorrhage - drug therapy Disability Evaluation Double-Blind Method Down-Regulation - drug effects Down-Regulation - physiology Drug Administration Schedule Female Humans Injections, Intravenous Male Medical sciences Middle Aged Neurology Neuropharmacology Neuroprotective agent Pharmacology. Drug treatments Placebos Potassium - blood Time Factors Treatment Outcome Vascular diseases and vascular malformations of the nervous system Vasodilator agents. Cerebral vasodilators
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!